Odomzo Side Effects
Generic name: sonidegib
Medically reviewed by Drugs.com. Last updated on Jul 25, 2024.
Note: This document provides detailed information about Odomzo Side Effects associated with sonidegib. Some dosage forms listed on this page may not apply specifically to the brand name Odomzo.
Applies to sonidegib: oral capsule.
Important warnings
This medicine can cause some serious health issues
Oral route (capsule)
Use of sonidegib during pregnancy can cause embryofetal death or severe birth defects.
Verify pregnancy status prior to initiating treatment and advise females of reproductive potential to use adequate contraception during treatment and for at least 20 months after discontinuation.
Male patients with a female partner of reproductive potential must be advised to use adequate contraception during treatment for at least 8 months after discontinuation.
Serious side effects of Odomzo
Along with its needed effects, sonidegib (the active ingredient contained in Odomzo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking sonidegib:
More common side effects
- difficulty with moving
- joint pain
- muscle aching or cramping
- muscle pains or stiffness
- muscle spasms
- swollen joints
Rare side effects
- dark-colored urine
- fever
- muscle stiffness
- unusual tiredness or weakness
Other side effects of Odomzo
Some side effects of sonidegib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
For healthcare professionals
Applies to sonidegib: oral capsule.
Musculoskeletal adverse events
- Very common (10% or more): Increased serum creatinine (92%), increased serum creatinine kinase (61%), muscle spasms (54%), musculoskeletal pain (32%), myalgia (19%)
- Uncommon (0.1% to 1%): Rhabdomyolysis[Ref]
75% of patients with increased serum creatinine had levels that remained within normal range.[Ref]
Dermatologic
- Very common (10% or more): Alopecia (53%), pruritus (10%)
- Common (1% to 10%): Rash, abnormal hair growth[Ref]
Metabolic
- Very common (10% or more): Hyperglycemia (51%), dysgeusia (46%), decreased weight (30%), decreased appetite (23%)
- Common (1% to 10%): Dehydration[Ref]
Nervous system
- Very common (10% or more): Dysgeusia (46%), headache (15%)[Ref]
Gastrointestinal
- Very common (10% or more): Increased lipase (43%), nausea (39%), diarrhea (32%), abdominal pain (18%), increased amylase (16%), vomiting (11%)
- Common (1% to 10%): Dyspepsia, constipation, GI reflux[Ref]
Other
Hematologic
Hepatic
- Very common (10% or more): Increased ALT (19%), increased AST (19%)[Ref]
Endocrine
- Frequency not reported: Amenorrhea[Ref]
References
1. Cerner Multum, Inc. "Australian Product Information."
2. (2015) "Product Information. Odomzo (sonidegib)." Novartis Pharmaceuticals
Frequently asked questions
More about Odomzo (sonidegib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: hedgehog pathway inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Odomzo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.